Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment

AbstractAnthracycline is a mainstay in treatment of many cancers including lymphoma and breast cancer among many others. However, anthracycline treatment can be cardiotoxic. Although anthracycline-induced cardiotoxicity is dose dependent, it can also occur early at the onset of treatment and even up to several years following completion of treatment. This review article focuses on the understanding of mechanisms of anthracycline-induced cardiotoxicity, the treatments, and recommended follow-up and preventive approaches.
Source: Heart Failure Reviews - Category: Cardiology Source Type: research